ClinicalTrials.gg
CompletedNCT00144300Updated Mar 14, 2014Results posted

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

A Phase 4 interventional study of Mirapex and Requip in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed at 21 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-03-14.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
12th of 26
246 · median 224
Started
2005
the only one that year
Phase 4
10 of 26
none open now
Registered
2nd of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 12th largest by enrollment, is the only one that started in 2005, is one of 10 in phase 4, and was the 2nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis and main criteria for inclusion. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

  1. Patients with idiopathic Parkinson's disease of less than 7 years characterized as Stage I-III by the Modified Hoehn and Yahr Scale and with a maximum of 6 months cumulative lifetime exposure to levodopa and/or dopamine agonist. Patients on current dopamine agonist therapy would require 14-day washout.
  2. Age at least 30 years.
  3. Women of must have a negative serum beta-HCG pregnancy test at the Screen (Baseline) visit and the patient must use adequate methods.
  4. Evidence of a personally signed and dated document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  5. Patients who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.

Exclusion criteria

Exclusion criteria

Main criteria for exclusion. The presence of any of the following would make a patient ineligible for enrollment into the study:

  1. Previous history of allergic response or complications with any dopaminergic agonist drug
  2. Atypical PD syndromes
  3. History of stereotactic brain surgery
  4. Positive (surface antigen) or (antibody)
  5. Surgery within 180 days of randomization which would negatively impact participation
  6. Folstein's (MMSE) score of 24 or less
  7. History of active epilepsy (seizure) in the past 1 year
  8. Third degree AV block or sick sinus syndrome
  9. Congestive heart failure, Class III or IV
  10. Unstable heart disease such as unstable angina, dysrhythmia, or myocardial infarction in prior 6 months
  11. Symptomatic orthostatic hypotension
  12. liver disease or renal disease
  13. Malignant melanoma or history of previously treated malignant melanoma.
  14. Prohibited medications taken (including any drug known to have potential retino-toxic effects taken in the prior 12 months; neuroleptics taken within prior 6 months, MAO inhibitors except rasagiline or selegiline taken within prior 3 months, beta-blockers taken to treat Parkinson's disease in the prior 30 days, and Coenzyme Q10 taken within 14 days)
  15. Albinism/Albinoidism of any degree, type or syndrome
  16. History of glaucoma with or without treatment
  17. Inherited or acquired retinopathy such as age-related macular degeneration with visual loss
  18. Sarcoidosis
  19. Diabetes mellitus of any degree even if diet or insulin controlled
  20. Best corrected visual acuity (BCVA) of less than 20/40 by ETDRS
  21. Refractive error of greater than minus-6 diopters
  22. Abnormal electroretinogram (ERG)
  23. Unable to dilate pupils
  24. History of severe eye trauma that might affect the outcome of the study
  25. History of psychosis
  26. Participation in other drug studies or use of investigational drugs within prior 30 days
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (actual)

Study arms

  • Active comparator
    Mirapex

    Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines

    Drug: Mirapex

  • Active comparator
    Requip

    Requip tablets three times daily (TID) dosing according to manufacturer's guidelines

    Drug: Requip

Interventions

  • Standard marketed product dispensed according to manufacturer's guidelines

  • DrugRequip

    Standard marketed product dispensed according to manufacturer's guidelines

06

What researchers measure

Primary outcomes

  1. Expert Panel Overall Assessment Following 2 Years on Drug

    Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments

    Time frame: up to 2 years

Secondary outcomes

  1. Expert Panel Overall Assessment Following 1 Year on Drug

    Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments

    Time frame: up to 1 years

  2. Hoehn and Yahr Scale at Baseline

    This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

    Time frame: Baseline

  3. Hoehn and Yahr Scale at 1 Year

    This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

    Time frame: Up to 1 year

  4. Hoehn and Yahr Scale at 2 Years

    This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

    Time frame: Up to 2 years

  5. Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline

    Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

    Time frame: Baseline

  6. Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year

    Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

    Time frame: 1 year

  7. Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year

    Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

    Time frame: Baseline, 1 year

  8. Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years

    Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

    Time frame: 2 years

  9. Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years

    Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

    Time frame: Baseline, 2 year

  10. Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline

    Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

    Time frame: Baseline

  11. Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year

    Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

    Time frame: 1 year

  12. Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year

    Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

    Time frame: Baseline, 1 year

  13. Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years

    Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

    Time frame: 2 years

  14. Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years

    Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

    Time frame: Baseline, 2 year

  15. Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline

    This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

    Time frame: Baseline

  16. Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year

    This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

    Time frame: 1 year

  17. Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year

    This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

    Time frame: Baseline, 1 year

  18. Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years

    This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

    Time frame: 2 years

  19. Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years

    This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

    Time frame: Baseline, 2 year

  20. Clinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs

    Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.

    Time frame: Screen (Baseline) and final visit (24 months)

07

Results

Posted Nov 4, 2011

Participant flow

Participant flow — Overall Study
MilestonePramipexoleRopinirole
Started121125
Completed9297
Not completed2928
Withdrew: Adverse event1816
Withdrew: Protocol violation13
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject66
Withdrew: Other reason (not specified)13

Outcome measures

PrimaryExpert Panel Overall Assessment Following 2 Years on Drug

Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments

Time frame:
up to 2 years
Reported as:
Number · Participants
Expert Panel Overall Assessment Following 2 Years on Drug
ParticipantsPramipexoleRopinirole
Have retinal deterioration3433
Have no retinal deterioration8186
Statistical analysis
  • Pramipexole vs Ropinirole · Risk ratio (rr): 1.07 · 95% CI 0.71 to 1.60
SecondaryExpert Panel Overall Assessment Following 1 Year on Drug

Expert panel of ophthalmologists assessed retinal deterioration by a review of the components of the comprehensive ophthalmology assessments

Time frame:
up to 1 years
Reported as:
Number · Participants
Expert Panel Overall Assessment Following 1 Year on Drug
ParticipantsPramipexoleRopinirole
Have retinal deterioration2821
Have no retinal deterioration8798
SecondaryHoehn and Yahr Scale at Baseline

This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

Time frame:
Baseline
Reported as:
Number · Participants
Hoehn and Yahr Scale at Baseline
ParticipantsPramipexoleRopinirole
Stage 00 ± 00 ± 0
Stage 12823
Stage 1.51119
Stage 27171
Stage 2.585
Stage 337
Stage 400
Stage 500
SecondaryHoehn and Yahr Scale at 1 Year

This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

Time frame:
Up to 1 year
Reported as:
Number · Participants
Hoehn and Yahr Scale at 1 Year
ParticipantsPramipexoleRopinirole
Stage 01 ± 11 ± 1
Stage 13322
Stage 1.5916
Stage 27072
Stage 2.588
Stage 306
Stage 400
Stage 500
SecondaryHoehn and Yahr Scale at 2 Years

This scale is an investigator-completed assessment of the degree of complications arising from Parkinson's disease. The scale ranges from 0 (No signs) to 5 (Bedridden)

Time frame:
Up to 2 years
Reported as:
Number · Participants
Hoehn and Yahr Scale at 2 Years
ParticipantsPramipexoleRopinirole
Stage 01 ± 10 ± 0
Stage 12723
Stage 1.5612
Stage 27473
Stage 2.51010
Stage 337
Stage 400
Stage 500
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline

Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

Time frame:
Baseline
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at Baseline8.0 ± 3.89.5 ± 4.7
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year

Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

Time frame:
1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 1 Year7.0 ± 4.38.4 ± 5.0
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year

Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

Time frame:
Baseline, 1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 1 Year-1.1 ± 3.4-1.1 ± 3.6
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years

Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

Time frame:
2 years
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Total Score at 2 Years8.4 ± 4.69.3 ± 5.2
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years

Part II of the UPDRS collected retrospective information on patient functioning in various activities of daily living. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 52.

Time frame:
Baseline, 2 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part II, Change From Baseline in Total Score at 2 Years0.4 ± 3.7-0.2 ± 4.0
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline

Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

Time frame:
Baseline
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at Baseline20.7 ± 9.322.4 ± 10.2
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year

Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

Time frame:
1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 1 Year17.7 ± 9.319.8 ± 10.9
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year

Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

Time frame:
Baseline, 1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 1 Year-3.0 ± 7.2-2.6 ± 6.1
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years

Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

Time frame:
2 years
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Total Score at 2 Years19.7 ± 9.920.9 ± 10.3
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years

Part III of the UPDRS contained the clinician-scored motor evaluation. Individual items scored from 0 (Normal) to 4 (Extreme dysfunction). The total score ranged from 0 to 56.

Time frame:
Baseline, 2 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Part III, Change From Baseline in Total Score at 2 Years-1.0 ± 7.9-1.5 ± 7.7
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline

This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

Time frame:
Baseline
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at Baseline28.8 ± 11.631.9 ± 13.4
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year

This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

Time frame:
1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 1 Year24.7 ± 11.828.2 ± 14.5
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year

This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

Time frame:
Baseline, 1 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 1 Year-4.1 ± 8.9-3.7 ± 8.2
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years

This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

Time frame:
2 years
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Total Score at 2 Years28.1 ± 12.930.2 ± 14.1
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years

This is the sum of Part II and Part III of the UPDRS. The total score ranged from 0 (Normal) to 108 (Extreme dysfunction).

Time frame:
Baseline, 2 year
Reported as:
Mean · Score on a scale
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years
Score on a scalePramipexoleRopinirole
Unified Parkinson's Disease Rating Scale (UPDRS), Parts II and III, Change From Baseline in Total Score at 2 Years-0.7 ± 10.1-1.7 ± 10.5
SecondaryClinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs

Clinical relevant abnormalities for clinical laboratory evaluations Biochemistry and Haematology) and Vital Signs. New abnormal findings or worsening of baseline conditions were reported.

Time frame:
Screen (Baseline) and final visit (24 months)
Reported as:
Number · participants
Clinical Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
participantsPramipexoleRopinirole
Haematocrit - Decrease12
Haemoglobin - Decrease85
Eosinophils - Increase40
Phosphate - Decrease02
Calcium - Increase10
Glucose - Decrease40

Adverse events

Collected over up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole—22/121 (18.2%)97/121 (80.2%)
Ropinirole—21/125 (16.8%)101/125 (80.8%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventPramipexoleRopinirole
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/1212/125
Atrial fibrillationCardiac disorders2/1211/125
Cardiac failure congestiveCardiac disorders2/1210/125
AppendicitisInfections and infestations2/1210/125
Femur fractureInjury, poisoning and procedural complications2/1210/125
Lower limb fractureInjury, poisoning and procedural complications2/1210/125
OsteoarthritisMusculoskeletal and connective tissue disorders2/1212/125
Coronary artery occlusionCardiac disorders0/1212/125
Chest discomfortGeneral disorders0/1212/125
Road traffic accidentInjury, poisoning and procedural complications1/1212/125
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPramipexoleRopinirole
SomnolenceNervous system disorders53/12171/125
NauseaGastrointestinal disorders31/12159/125
DizzinessNervous system disorders27/12135/125
FatigueGeneral disorders27/12125/125
HeadacheNervous system disorders15/12127/125
InsomniaPsychiatric disorders19/12127/125
ConstipationGastrointestinal disorders18/12126/125
Oedema peripheralGeneral disorders22/12118/125
NasopharyngitisInfections and infestations17/12116/125
Back painMusculoskeletal and connective tissue disorders17/1219/125

Baseline characteristics

Age, Continuous
Age, Continuous(years)PramipexoleRopiniroleTotal
Mean57.5 ± 9.359.1 ± 8.758.3 ± 9.0
Age, Customized
Age, Customized(Participants)PramipexoleRopiniroleTotal
< 50 years231740
50 to < 65 years7174145
65 to < 75 years213051
>= 75 years6410
Sex: Female, Male
Sex: Female, Male(Participants)PramipexoleRopiniroleTotal
Female424789
Male7978157
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PramipexoleRopiniroleTotal
Asian112
Black7310
White113121234
Height
Height(centimeters)PramipexoleRopiniroleTotal
Mean171.3 ± 9.2171.6 ± 12.4171.5 ± 10.9
Weight
Weight(kilograms)PramipexoleRopiniroleTotal
Mean81.32 ± 17.6482.80 ± 18.3982.07 ± 18.00
Duration of Parkinson's disease diagnosis
Duration of Parkinson's disease diagnosis(years)PramipexoleRopiniroleTotal
Mean0.97 ± 1.151.29 ± 1.701.13 ± 1.46
Hoehn and Yahr stage
Hoehn and Yahr stage(Participants)PramipexoleRopiniroleTotal
Stage 0000
Stage 1282351
Stage 1.5111930
Stage 27171142
Stage 2.58513
Stage 33710
Stage 4000
Stage 5000

1 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • 248.538.00007 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 248.538.00008 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 248.538.00021 Boehringer Ingelheim Investigational Site
    Fountain Valley, California, United States
  • 248.538.00022 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 248.538.00001 Boehringer Ingelheim Investigational Site
    New Haven, Connecticut, United States
  • 248.538.00002 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 248.538.00016 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 248.538.00023 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 248.538.00013 Boehringer Ingelheim Investigational Site
    Atlanta, Georgia, United States
  • 248.538.00009 Boehringer Ingelheim Investigational Site
    Augusta, Georgia, United States
  • 248.538.00011 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.538.00005 Boehringer Ingelheim Investigational Site
    Baltimore, Maryland, United States
  • 248.538.00014 Boehringer Ingelheim Investigational Site
    Southfield, Michigan, United States
  • 248.538.00010 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.538.00015 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.538.00020 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.538.00012 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 248.538.00006 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 248.538.00004 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 248.538.00003 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 248.538.00017 Boehringer Ingelheim Investigational Site
    Morgantown, West Virginia, United States
09

References and documents

Publications

  • Seiple W, Jennings D, Rosen RB, Borchert L, Canale L, Fagan N, Gordon MF. Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease. Parkinsons Dis. 2016;2016:8298503. doi: 10.1155/2016/8298503. Epub 2016 Dec 18. PubMed 28078162 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2005
First posted
Sep 5, 2005
Start
Jan 2005
Primary completionActual
Sep 2010
Results first posted
Nov 4, 2011
Last update
Mar 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00144300
Responsible party
Sponsor
First posted
Sep 5, 2005
Start date
Jan 2005
Primary completion
Sep 2010
Results posted
Nov 4, 2011
Last update
Mar 14, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pramipexole · Ropinirole

Start the discussion